Abstract
Purpose
Tissue inhibitor of matrix metalloproteinase (TIMP)-3 has many functions, including preventing the constituent formation of tumor necrosis factor-alpha (TNFα) in tissue. Sorsby macular dystrophy is caused by a mutation in the gene responsible for TIMP-3, suggesting a potential treatment.
Methods
Comprehensive ophthalmologic examination with multimodal imaging to include optical coherence tomography (OCT) and OCT angiography were used to evaluate a patient with Sorsby fundus dystrophy treated first with intravitreal triamcinolone, then with adalimumab.
Results
A 35-year-old woman presented in 2003 with aggressive macular neovascularization in both eyes related to Sorsby macular dystrophy c.610A>T (p.Ser204Cys). Her visual acuity was 20/25 in the right and 20/400 in the left eye. She was treated with periodic intravitreal injections of 4 mg triamcinolone, which caused the neovascularization to become inactive. When switched to intravitreal bevacizumab, she showed disease activity. She was switched back to intravitreal triamcinolone with minimal signs of exudation and hemorrhage. Because of the high lifetime risk of complication, she was switched to subcutaneous adalimumab and in follow-up over 18 months had no signs of disease activity. The visual acuity in the right eye was 20/20.
Conclusions
TIMP3 has numerous effects including controlling local TNFα production. It is possible with the mutation in the gene for TIMP-3, abnormally high tissue levels of TNFα are produced in the eye. Direct inhibition of TNFα action by adalimumab offers a molecularly targeted approach to the disease pathophysiology and merits increased study.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Sorsby A, Mason MEJ. A fundus dystrophy with unusual features. Br J Ophthalmol. 1949;33:67–97.
Capon MRC, et al. Sorsby’s fundus dystrophy: a light and electron microscopic study. Ophthalmology. 1989;96:1769–77.
Duke-Elder S, Perkins ES. Diseases of the uveal tract. System of ophthalmology. London: Kimpton; 1966.
Weber BHF, Vogt G, Pruett RC, Stöhr H, Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby’s fundus dystrophy. Nat Genet. 1994;8:352–6.
Kawai T, Elliott KJ, Scalia R, Eguchi S. Contribution of ADAM17 and related ADAMs in cardiovascular diseases. Cell Mol Life Sci. 2021;78:4161–87.
Smookler DS, et al. Cutting edge: tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol. 2006;176:721–5.
Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49–62.
Spaide RF. Long-term visual acuity preservation in Sorsby fundus dystrophy with corticosteroid treatment. Retin Cases Br Rep. 2019. https://doi.org/10.1097/ICB.0000000000000946.
Hongisto H, et al. In vitro stem cell modelling demonstrates a proof-of-concept for excess functional mutant TIMP3 as the cause of Sorsby fundus dystrophy. J Pathol. 2020;252:138–50.
Qi JH, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med. 2003;9:407–15.
Mohammed FF, et al. Abnormal TNF activity in Timp3−/− mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet. 2004;36:969–77.
Meunier I, et al. A new autosomal dominant eye and lung syndrome linked to mutations in TIMP3 gene. Sci Rep. 2016;6:1–9.
An E, Gordish-Dressman H, Hathout Y. Effect of TNF-alpha on human ARPE-19-secreted proteins. Mol Vis. 2008;14:2292–303.
Wu J, Sun X. Complement system and age-related macular degeneration: drugs and challenges. Drug Des Dev Ther. 2019;13:2413–25.
Hageman GS, et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog Retinal Eye Res. 2001;20:705–32.
Acknowledgements
The study was funded in part by the Macula Foundation, Inc., which had no input in terms of content.
Funding
Topcon Medical Systems, Regeneron, Roche, Genentech, Heidelberg Engineering, Adverum Biotechnologies, and DORC.
Author information
Authors and Affiliations
Contributions
This is a single author study.
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Spaide, R.F. Treatment of Sorsby fundus dystrophy with anti-tumor necrosis factor-alpha medication. Eye 36, 1810–1812 (2022). https://doi.org/10.1038/s41433-021-01735-3
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41433-021-01735-3
This article is cited by
-
Bevacizumab/ranibizumab/triamcinolone
Reactions Weekly (2021)
